NCT07042919View on ClinicalTrials.gov

Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 4, 2026

Primary Completion Date

March 4, 2029

Study Completion Date

March 4, 2031

Conditions
Advanced Hepatocellular CarcinomaCirrhosisStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo urine and blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Zanzalintinib

Given PO

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER